HAVCR2 and cancer: Although these results need further validation, this underscores the previously mentioned need for more data of soluble immune checkpoints in various cancers, especially since several anti-PD-1 and other immunotherapy trials are ongoing in GC/GEJ, and multiple clinical trials targeting TIM-3 or Gal-9 in various cancer types are underway.1